Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | +29.91% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.41 | N/A | +29.91% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed confidence in the company's long-term strategy. They emphasized the importance of innovation and customer engagement.
Management highlighted ongoing investments in R&D to drive future growth.
They noted a strong demand for their products despite current market challenges.
10X Genomics reported a narrower-than-expected loss per share, which was seen as a positive sign by investors. However, the stock reaction remained flat, indicating that investors may be cautious due to the lack of revenue data and guidance. The company's focus on R&D and product demand could position it well for future growth, but uncertainty remains.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ADAPTIVE BIOTECHNOLO
Aug 10, 2020